Summary
Simon Hill critically examines the Fatty15 supplement with lipid researcher Bill Harris. They evaluate whether C15:0 qualifies as an essential fatty acid, scrutinize the quality of existing research, and discuss whether the observational associations between C15:0 levels and reduced disease risk prove causation. Harris brings an independent perspective as a lipid science expert, weighing the promising cell data against the limited human clinical evidence.
Key Points
- Bill Harris provides an independent scientific evaluation of the C15:0 research
- The observational data linking C15:0 to reduced metabolic disease is compelling but not proof of causation
- Only two human RCTs have been published with modest results
- Most research has been conducted by the company's own founder, raising independence concerns
- The "essential fatty acid" classification is not yet recognized by scientific authorities
- Cell-based studies show promising AMPK activation and mTOR inhibition
- Hill and Harris provide balanced analysis of what the science does and does not support
Key Moments
Critical evaluation of Fatty15 supplement claims
Simon Hill takes a skeptical but fair look at whether the science behind Fatty15 supports its marketing claims.
"So, this is a saturated fat, an odd-chain saturated fat that really has kind of been Stephanie Van Watson, who first studied this fat in dolphins. And then her team have gone from there and researched this fatty acid alongside some independent studies that also exist. And they've patented this C15 supplement that they market."
